TransGene, NEC, and BostonGene have entered a strategic collaboration to test TG4050, an investigational personalized vaccine that aims to treat ovarian and head and neck cancers, according to a press release. TG4050 is an individualized therapy that stimulates a patient’s immune system into attacking cancer cells by “teaching” it which cells are malignant — based on the presence of certain mutated cancer proteins, called neoantigens, found in tumor tissues. The partners will first use NEC’s artificial intelligence-based…
You must be logged in to read/download the full post.
The post 3 Companies Join Forces to Test Personalized ‘Teaching’ Vaccine for Ovarian Cancer appeared first on BioNewsFeeds.